Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Solutions LLC

Neither a doctor nor a teaching hospital

Research payments

$2,351,848

674 payments

Through program year 2025, Clinical Research Solutions LLC is reported as receiving $2,351,848 in research payments, across 674 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,425 5
2024 Research $7,527 10
2023 Research $67,854 23
2022 Research $199,956 69
2021 Research $907,073 120
2020 Research $742,282 264
2019 Research $424,730 183

Breakdown

Who paid Research payments · program years 2019–2025
  1. Abbott Laboratories $426,087 13 payments
  2. Pfizer Inc. $406,092 135 payments
  3. AbbVie, Inc. $342,178 94 payments
  4. Becton, Dickinson and Company $168,320 2 payments
  5. Aesculap Biologics, LLC $157,117 40 payments
  6. Intercept Pharmaceuticals, Inc. $121,964 86 payments
  7. Vanda Pharmaceuticals Inc. $108,565 25 payments
  8. Janssen Research & Development, LLC $107,647 67 payments
  9. Clovis Oncology, Inc. $91,393 68 payments
  10. Allergan Inc. $82,715 16 payments
Studies the money was for Research payments · program years 2019–2025
  1. Alinity m Resp-4-Plex Specimen Collection Protocol $248,022 8 payments
  2. M16-046 $208,239 39 payments
  3. Abbott RealTime SARS-CoV-2 Specimen Collection Protocol $178,065 5 payments
  4. VerHome $168,320 2 payments
  5. Novocart 3D for the Treatment of Articular Cartilage of the Knee (N3d) $157,117 40 payments
  6. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer $125,562 23 payments
  7. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $123,923 79 payments
  8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis $102,323 24 payments
  9. A Phase 2A Multicenter Randomized Doubleblind Placebocontrolled 16Week Study Evaluating the Safety and Efficacy of Pf06650833 Pf06700841 and Pf06826647 in Adults With Moderate to Severe Hidradenitis Suppurativa $81,328 11 payments
  10. 1011866 $74,321 53 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record